Newport Beach, CA – According to filings with the U.S. Securities and Exchange Commission, Equinox Ophthalmic is raising $22 Million in a new round of investment. Sources indicate as part of senior management Chief Executive Officer, John Berdahl played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Equinox Ophthalmic

Equinox is currently engaged in FDA clinical studies for treatment options for glaucoma care and management. If you are a patient who would like to be considered for future clinical trials, contact us for more information. Equinox is pioneering a new understanding of glaucoma based on deep exploration into the physics of the eye and eye pressure. This new understanding is based on the discovery and research into Multi-Pressure Glaucoma Management, or MGM.

To learn more about Equinox Ophthalmic, visit http://equinoxus.com/

Contact:
John Berdahl, Chief Executive Officer
949-468-6284
https://www.linkedin.com/in/johnberdahl/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved